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Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the 
central nervous system. It is relatively common with a frequency of 0.1-0.2%
in Northern European countries. The age at onset is most often between 20
and 40 years. Women are affected more often than men with a female-male
ratio between 1.4. and 2 1.
Clinical symptoms
Clinically, MS is characterized by focal neurological symptoms of the optic
nerves, spinal cord and brain. The frequency of symptoms at presentation is
related to age2. The most common initial symptom at any age is sensory,
consisting of tingling or numbness. Optic neuritis is much more prevalent as
a presenting symptom in patients under 20 than patients over 40 years old.
Insidious motor symptoms, typically chronic progressive myelopathy, are
characteristic of patients in their forties. Other common initial symptoms are
diplopia, vertigo, limb ataxia, impairment of balance or acute motor 
symptoms.
As the disease progresses additional symptoms may be spasticity, pain,
fatigue, dysarthria, disorders of micturition and bowel voiding, sexual distur-
bances, cognitive dysfunction and paroxysmal phenomena (this list is not
limitative). Disability is measured by various scales3-6 that all seem to have
their own advantages and limitations .
Disease course
Most often the initial course is relapsing-remitting (80%), with exacerbations
and remissions during which the patient recovers completely or partially 7.
The relapsing phase is followed by a secondary progressive phase in approxi-
mately two thirds of the patients after on average 10-15 years. During the
secondary progressive phase there is gradually worsening disability in
between eventual relapses. However, up to one third of the patients do not
develop progressive disability and remain unimpaired for many years 
(benign MS). A smaller number of patients (10-15%) experiences gradual 
progression from onset and this course is called primary progressive. Rarely,
the disease is rapidly fatal.
Diagnosis
The diagnosis of MS is based upon evidence of two or more lesions in the
central nervous system (CNS), dissociated both in time and space. Initially,
the Schumacher criteria8 were used to identify patients with clinically 
definite MS for inclusion in clinical trials. According to these criteria, lesions
should be present predominantly in the white matter and disseminated in
time and space.
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Table 1: The Schumacher criteria
Evidence on examination or in patient’s history of two or more lesions in the CNS
Relapsing remitting disease Two or more episodes separated by at least
one month and lasting a minimum of 24 
hours
Progressive disease Persistent deterioration for six months
Onset between ages of 10 and 50 years 
No better explanation for the symptoms in the opinion of a physician “competent in
clinical neurology”
In 1983 Poser 9 proposed criteria that incorporated also paraclinical and 
laboratory findings to be used as support for the diagnosis (Table 2). These
criteria were used to include patients in our studies as reported in this 
thesis.
Table 2: The Poser criteria 
Category Attacks Clinical Paraclinical CSF
evidence evidence
A. Clinically definite MS
CDMS A1 2 2
CDMS A2 2 1 and 1
B. Laboratory-supported 
definite MS
LSDMS B1 2 1 or 1 +
LSDMS B2 1 2 +
LSDMS B3 1 1 and 1 +
C. Clinically probable MS
CPMS C1 2 1
CPMS C2 1 2
CPMS C3 1 1 and 1
Laboratory-supported 
probable MS
LSPMS D1 2 +
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In the cerebrospinal fluid (CSF), the presence of abnormally high levels of
immunoglobulin G (IgG) is supportive of MS. To exclude the possibility of
leakage of IgG through an impaired blood-brain barrier, the concentrations
of IgG and albumin in CSF and serum are compared and expressed as the
IgG-index.
IgG in CSF albumin in CSF
:
IgG in serum albumin in serum
CSF and plasma are also examined by isoelectric focussing (IEF). Oligoclonal
IgG bands present in CSF and not in serum are strongly supportive of the
diagnosis of MS. However, oligoclonal bands can also be found in patients
with other diseases like inflammatory and /or infectious diseases of the CNS.
Of MS patients, 70% have an IgG index greater than 0.7 and 95% have oligo-
clonal bands10. A modestly increased number of white blood cells in the CSF
(5-35/mm3 ) is found in about half of MS patients, whereas numbers higher
than 35-50/mm3 are very rare.
Evoked potentials may provide evidence of focal dysfunction within the
optic nerve or CNS, even if symptoms are too subtle to be found at clinical
examination. Visual, auditory, somatosensory and motor evoked potentials
can be investigated. There is, however, only limited information as to the 
sensitivity and specificity of evoked potentials in MS.
More recently, new criteria incorporating also the results of magnetic 
resonance imaging (MRI) have been introduced 11,12.
Pathogenesis
In the pathogenesis, autoimmunity is likely to play a major role13. Proteins
that form part of the myelin sheath are suspected to be the target of the
immunological reaction. However, some authors examine an alternative
hypothesis of pathogenesis, suggesting that MS is a neurodegenerative and
metabolic disorder with polygenic influence14. The heterogeneity of demyeli-
nating lesions at pathological examination leaves room for both theories15.
Patterns showing similarities with T-cell-mediated or T-cell plus antibody-
mediated autoimmune encephalomyelitis as well as patterns suggestive of
primary oligodendrocyte dystrophy were found.
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Etiology
There is evidence for both genetic and environmental factors playing a role
in susceptibility to MS. Indications for environmental factors include the 
correlation between prevalence and geographic localization16,17, migration
studies 18-22, possible clustering23-26 and reports of specific antibodies in
bodyfluids 27,28. The available epidemiologic data were recently reviewed by
Marrie29. Indications for genetic factors are the association with specific HLA
alleles, increased risk for relatives proportional to the amount of DNA shared,
twin studies and racial differences (chapter 2).
Aims and scope of this thesis
Subject of this thesis are the genetic factors playing a role in MS. These fac-
tors will be approached from a genetic epidemiological point of view. Major
questions in this field are: what is the disease model of MS, regarding the
role of genetic and environmental factors?  Where are the genetic factors
localized within the genome?  What is the contribution of each locus? How is
their inheritance mode (dominant, recessive, intermediate)? Do loci interact? 
Chapter 2 provides an review of genetic epidemiological studies with
emphasis on genome screens. Since a large part of the genome had been
excluded for a locus with major contribution to susceptibility, we focussed on
the HLA region, the only region that has repeatedly been found to be
involved in MS. In our first study (chapter 3) we tried to finemap a locus
within the HLA region, using a newly developed method of haplotype 
sharing analysis. Chapter 4 describes the inheritance mode of the region we
finemapped previously. In chapter 5 we review the differences between dif-
ferent types of MS (relapsing-onset and primary progressive) and investigate
whether in our population a genetic difference can be found in the HLA
region.
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